secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001326110-25-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio Q1 net product revenue ~$16.5M (+129% QoQ); submits sBLA for NMIBC papillary disease
--------------------------------------------------------------------------------

- Q1 2025 net product revenue ~$16.5M (+129% QoQ from $7.2M in Q4 2024).
- Unit sales volume in Q1 2025 grew 150% QoQ exceeding FY2024 total; March up 69% MoM.
- Submitted sBLA to FDA for ANKTIVA+BCG in BCG-unresponsive NMIBC papillary disease; 93% cystectomy avoidance at 20.7 months.
- Submitted Expanded Access Protocol (EAP) for ANKTIVA to treat lymphopenia after RMAT designation in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000044/0001326110-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000044/ibrx-20250415.htm
  HTML page:      https://secwatch.observer/filing/0001326110-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer